Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
SPHD vs XBI: how they differ
SPHD and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Invesco S&P 500 High Dividend Low Volatility ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, SPHD and XBI hold 0% of their money in the same securities at the same weight.
| Only in SPHD | Only in XBI |
|---|---|
| Verizon Communications Inc. 3.49% | Apogee Therapeutics Inc 1.49% |
| Altria Group, Inc. 3.45% | Moderna Inc 1.41% |
| Healthpeak Properties, Inc. 3.24% | Twist Bioscience Corp 1.41% |
| Kraft Heinz Co. (The) 3.03% | Oruka Therapeutics Inc 1.38% |
| Pfizer Inc. 2.99% | Kymera Therapeutics Inc 1.36% |
| Franklin Resources, Inc. 2.82% | Viking Therapeutics Inc 1.31% |
| VICI Properties Inc. 2.68% | Praxis Precision Medicines Inc 1.29% |
| ONEOK, Inc. 2.66% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| SPHD Invesco S&P 500 High Dividend Low Volatility ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Invesco | State Street |
| What it is | S&P 500 High Dividend Low Volatility | SPDR S&P Biotech |
| Total return, 1 year | +8.6% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −8.9 pts | +46.5 pts |
| Expense ratio | 0.30% | 0.35% |
| Already in the S&P 500 | 95.7% | 8.5% |
| Holdings | 49 | 150 |
SPHD in plain words
SPHD is an index equity fund tracking the S&P 500 High Dividend Low Volatility. Over the year to Sep 11, 2026 it returned +8.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.30% a year. By its holdings filed for May 31, 2026, 96% of the fund by weight is stocks the S&P 500 also holds, across 49 positions, with the top ten at 29.3%. It sat 4.1% below its high of Aug 24, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, SPHD or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, SPHD returned +8.6% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, SPHD or XBI?
- SPHD charges 0.30% a year and XBI charges 0.35%, so SPHD is cheaper. Fees come from each fund's prospectus.
- How much do SPHD and XBI overlap with the S&P 500?
- By their latest filed holdings, 96% of SPHD and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, SPHD against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/SPHD-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources